Multiple Myeloma MRD tracking in blood using ultra sensitive Mass Spectrometry (M-inSight)
In collaboration with Sanofi.
During ASH 2023, Sebia presented data collected with their innovative assay, M-inSight, to monitor low level (MRD) disease burden in multiple myeloma using only 2 microliters of serum. M-inSight assay shows the possibility to monitor control disease and provide actionable information with a non invasive testing.